Skip to menu Skip to content Skip to footer
Associate Professor Jakob Begun
Associate Professor

Jakob Begun

Email: 

Overview

Background

Associate Professor Jakob Begun is the IBD Group leader in the Immunity, Infection, and Inflammation Program at Mater Research University of Queensalnd, and has a basic and translational laboratory at the Translational Research Institute in Brisbane. He is an Associate Professor in the University of Queensland Faculty of Medicine. After completing his Bachelor of Science at Cornell University Jakob attended Cambridge University where he completed an MPhil in Biochemistry. He then moved on to Harvard Medical School where he completed his MD and PhD in genetics studying the host pathogen interaction using C. elegans as a model system. He completed his clinical training in internal medicine at Brigham and Women’s hospital and went on to complete general gastroenterology training at Massachusetts General Hospital (MGH) as well as advanced training in the treatment of Inflammatory Bowel Disease (IBD).

Dr Begun first joined Mater Research - University of Queensland in 2014, and at the same time received a clinical staff appointment in Gastroenterology at the Mater Hospital Brisbane. His clinical activities are focussed on the treatment and mangement of patients with IBD. He is the director of the IBD unit at the Mater Hospital Brisbane and at the Mater Young Adult Health Centre Brisbane .In January 2015 he was awarded the University of Queensland Reginald Ferguson Fellowship in Gastroenterology to support his research activity. He leads a basic and translational laboratory at the Translational Research Institute investigating the interaction between the innate immune system and the gut microbiome, as well as genetic contributions to disease. He also performs clinical research examining predictors of response to therapy, minimising barriers of care for adolescents and young adults with IBD, improving outcomes in pregnancy and IBD, and the use of intestinal ultrasound in IBD. He is the chair of the Gastroenterology Society of Australia-IBD Faculty and of the president of the Gastroenterology Network of Intestinal Ultrasound (GENIUS).

Availability

Associate Professor Jakob Begun is:
Available for supervision
Media expert

Qualifications

  • Bachelor of Biology, Cornell University
  • Doctoral Diploma of Medicine, Harvard University
  • Doctor of Philosophy of Genetics, Harvard University
  • Member, Gastroenterological Society of Australia, Gastroenterological Society of Australia
  • Fellow, Royal Australasian College of Physicians, Royal Australasian College of Physicians

Research impacts

Inflammatory bowel disease(IBD) is a complex disease with genetic and environmental triggers. The microbiota is one of the biggest environmental contributors and interest in its impact on human health and disease is a growing. Studies in IBD have led the way in identifying disease associated microbial signals, but has not yet led to any new therapies.

As a clinician-scientist I am driven by my patients’ needs to address all aspects of their disease: including genetic and environmental risk factors, disease monitoring, and developing novel therapeutics. My tranlsational research program contributes to KNOWLEDGE IMPACT by discovering the function of IBD-susceptibility genes and anti-inflammatory bio-actives produced by the gut microbiota. My clinical research program advances HEALTH IMPACT by optimizing patient monitoring through evidence-based use of biochemical tests and imaging technology.

-Knowledge Impact. My research into the interaction between IBD susceptibility genes and bacterial handling has been highly cited, and led to an NHMRC collaborative project grant.

-Health Impact. My research program into advances in patient monitoring has led to the application for faecal calprotectin testing to be covered by the Medicare Benefit Scheme – which will have a direct impact on patient monitoring in the clinic. Additionally my monitoring research into the use of intestinal ultrasound has led to the formation of the Gastroenterology Network of Intestinal Ultrasound and the increase in ultrasound use in IBD patients in Australia.

Works

Search Professor Jakob Begun’s works on UQ eSpace

185 works between 1996 and 2024

1 - 20 of 185 works

2024

Journal Article

Group B Streptococcus vaginal colonisation throughout pregnancy is associated with decreased Lactobacillus crispatus and increased Lactobacillus iners abundance in the vaginal microbial community

Maidment, Toby I., Pelzer, Elise S., Borg, Danielle J., Cheung, Eddie, Begun, Jake, Nitert, Marloes Dekker, Rae, Kym M., Clifton, Vicki L. and Carey, Alison J. (2024). Group B Streptococcus vaginal colonisation throughout pregnancy is associated with decreased Lactobacillus crispatus and increased Lactobacillus iners abundance in the vaginal microbial community. Frontiers in Cellular and Infection Microbiology, 14 1435745. doi: 10.3389/fcimb.2024.1435745

Group B Streptococcus vaginal colonisation throughout pregnancy is associated with decreased Lactobacillus crispatus and increased Lactobacillus iners abundance in the vaginal microbial community

2024

Journal Article

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

Choy, Matthew C, Li Wai Suen, Christopher F D, Con, Danny, Boyd, Kristy, Pena, Raquel, Burrell, Kathryn, Rosella, Ourania, Proud, David, Brouwer, Richard, Gorelik, Alexandra, Liew, Danny, Connell, William R, Wright, Emily K, Taylor, Kirstin M, Pudipeddi, Aviv, Sawers, Michelle, Christensen, Britt, Ng, Watson, Begun, Jakob, Radford-Smith, Graham, Garg, Mayur, Martin, Neal, van Langenberg, Daniel R, Ding, Nik S, Beswick, Lauren, Leong, Rupert W, Sparrow, Miles P and De Cruz, Peter (2024). Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial. The Lancet Gastroenterology & Hepatology, 9 (11), 981-996. doi: 10.1016/s2468-1253(24)00200-0

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

2024

Journal Article

Reliability of intestinal ultrasound for evaluating Crohn’s disease activity using point-of-care and central reading

Goodsall, Thomas M., An, Yoon-Kyo, Andrews, Jane M., Begun, Jakob, Friedman, Antony B., Lee, Andrew, Lewindon, Peter J., Spizzo, Paul, Rodgers, Nick, Taylor, Kirstin M., White, Lauren S., Wilkens, Rune, Wright, Emily K., Zou, Lily, Maguire, Bryan R., Parker, Claire E., Rémillard, Julie, Novak, Kerri L., Panaccione, Remo, Feagan, Brian G., Jairath, Vipul, Ma, Christopher and Bryant, Robert V. (2024). Reliability of intestinal ultrasound for evaluating Crohn’s disease activity using point-of-care and central reading. Clinical Gastroenterology and Hepatology. doi: 10.1016/j.cgh.2024.08.007

Reliability of intestinal ultrasound for evaluating Crohn’s disease activity using point-of-care and central reading

2024

Journal Article

A truncation mutant of adenomatous polyposis coli impairs apical cell extrusion through elevated epithelial tissue tension

Gan, Wan J., Giri, Rabina, Begun, Jakob, Abud, Helen E., Hardeman, Edna C., Gunning, Peter W., Yap, Alpha S. and Noordstra, Ivar (2024). A truncation mutant of adenomatous polyposis coli impairs apical cell extrusion through elevated epithelial tissue tension. Cytoskeleton. doi: 10.1002/cm.21893

A truncation mutant of adenomatous polyposis coli impairs apical cell extrusion through elevated epithelial tissue tension

2024

Journal Article

Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immunemediated inflammatory diseases-an observational study

Jones, Graeme, Calao, Miriam, Begun, Jakob, Sin, Shirley, Kouhkamari, Mahsa H., Young, Elisa, Fernández-Peñas, Pablo, Watts, Alan and Östör, Andrew J. (2024). Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immunemediated inflammatory diseases-an observational study. PLoS One, 19 (6 June) e0300624. doi: 10.1371/journal.pone.0300624

Impact of a Patient Support Program on time to discontinuation of adalimumab in Australian adult patients with immunemediated inflammatory diseases-an observational study

2024

Journal Article

High technical success rate of endoscopic balloon dilatation reduces surgical requirement for patients with stricturing Crohn’s disease

Lim, Emily, Thai, Maxter, An, Yoon-Kyo, Hendy, Peter, Alchlaihawi, Mahmoud, Leong, Rupert, Connor, Susan, Ng, Watson, Gu, Bonita, Thin, Lena, Sparrow, Miles, Gilmore, Robert, Taylor, Kirstin, Sallis, Olivia, Andrews, Jane M., Daker, Charlotte, Gearry, Richard B., Wark, Gabrielle, Ghaly, Simon, Begun, Matt, Krishnaprasad, Krupa, Wu, Tianhong, Ruddick-Collins, Leonie, Schreiber, Veronika, Okano, Satomi, Radford-Smith, Graham, Schulberg, Julien, van Langenberg, Daniel and Begun, Jakob (2024). High technical success rate of endoscopic balloon dilatation reduces surgical requirement for patients with stricturing Crohn’s disease. GastroHep, 2024 (1) 3686618, 1-10. doi: 10.1155/2024/3686618

High technical success rate of endoscopic balloon dilatation reduces surgical requirement for patients with stricturing Crohn’s disease

2024

Journal Article

Does Improving Depression Symptoms in Young Adults With Inflammatory Bowel Disease Alter Their Microbiome?

Davies, Julie M, Teh, Jing Jie, Ewais, Tatjana and Begun, Jakob (2024). Does Improving Depression Symptoms in Young Adults With Inflammatory Bowel Disease Alter Their Microbiome?. Inflammatory Bowel Diseases. doi: 10.1093/ibd/izae121

Does Improving Depression Symptoms in Young Adults With Inflammatory Bowel Disease Alter Their Microbiome?

2024

Conference Publication

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

Khoo, Emi, Amiss, Anna, Ding, Nik S., Bryant, Robert V., Mohsen, Waled, Connor, Susan J., Leong, Rupert, Croft, Anthony, Lynch, Kate D., Sparrow, Miles, De Cruz, Peter, An, Yoon-Kyo, Holtmann, Gerald J. and Begun, Jakob (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. Digestive Disease Week (DDW) 2024, Washington, DC, United States, 18-21 May 2024. Philadelphia, PA, United States: Elsevier. doi: 10.1016/s0016-5085(24)00988-0

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

2024

Conference Publication

A Cost-effective Inflammatory Bowel Disease Flare Management Pathway Utilising Rapid Access Intestinal Ultrasound And Nurse-led Triage To Achieve Hospital Avoidance With High Patient Satisfaction

Fernandes, Richard G., Khoo, Emi, Harris, Heidi Jensen, Gilmore, Robert, Khaing, Myat Myat, Begun, Jakob and An, Yoon-Kyo (2024). A Cost-effective Inflammatory Bowel Disease Flare Management Pathway Utilising Rapid Access Intestinal Ultrasound And Nurse-led Triage To Achieve Hospital Avoidance With High Patient Satisfaction. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier BV. doi: 10.1016/s0016-5085(24)01652-4

A Cost-effective Inflammatory Bowel Disease Flare Management Pathway Utilising Rapid Access Intestinal Ultrasound And Nurse-led Triage To Achieve Hospital Avoidance With High Patient Satisfaction

2024

Conference Publication

Variation In Outcomes In Inflammatory Bowel Disease At Ten Australasian Centres - Crohn's Colitis Cure (CCC) Data Insights Program

McNamara, Jack, Wilson, William E., Pipicella, Joseph L., Ghaly, Simon, Gearry, Richard, Begun, Jakob, Ng, Watson, Lynch, Kate D., Lawrance, Ian C., Schultz, Michael, Walker, Gareth J., Radford-Smith, Graham L., Andrews, Jane M. and Connor, Susan J. (2024). Variation In Outcomes In Inflammatory Bowel Disease At Ten Australasian Centres - Crohn's Colitis Cure (CCC) Data Insights Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)02405-3

Variation In Outcomes In Inflammatory Bowel Disease At Ten Australasian Centres - Crohn's Colitis Cure (CCC) Data Insights Program

2024

Conference Publication

The Real-world Use Of Five-aminosalicylate (5ASA) Treatment For Ulcerative Colitis In Australia And New Zealand: Crohn's Colitis Cure (CCC) Data Insight's Program

Pipicella, Joseph L., McNamara, Jack, Wilson, William E., Lynch, Kate D., Walker, Gareth J., Begun, Jakob, Lawrance, Ian C., Ghaly, Simon, Radford-Smith, Graham L., Williams, Astrid-Jane, Gearry, Richard, Schultz, Michael, Brett, Laurel, Andrews, Jane M. and Connor, Susan J. (2024). The Real-world Use Of Five-aminosalicylate (5ASA) Treatment For Ulcerative Colitis In Australia And New Zealand: Crohn's Colitis Cure (CCC) Data Insight's Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)03792-2

The Real-world Use Of Five-aminosalicylate (5ASA) Treatment For Ulcerative Colitis In Australia And New Zealand: Crohn's Colitis Cure (CCC) Data Insight's Program

2024

Conference Publication

Dose Escalated Infliximab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

Alshiwanna, Basheer, McNamara, Jack, Wilson, William E., Pipicella, Joseph L., Ghaly, Simon, Gearry, Richard, Begun, Jakob, Williams, Astrid-Jane, Lynch, Kate D., Lawrance, Ian C., Schultz, Michael, Walker, Gareth J., Radford-Smith, Graham L., Connor, Susan J. and Andrews, Jane M. (2024). Dose Escalated Infliximab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)03074-9

Dose Escalated Infliximab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

2024

Journal Article

Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: a Randomized Controlled Trial

Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj, Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark G., De Cruz, Peter, Fung, Caroline Lan-San, Redmond, Diane, Chan, Webber, Mourad, Fadi, Kermeen, Melissa and Leong, Rupert W. (2024). Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: a Randomized Controlled Trial. Clinical Gastroenterology and Hepatology, 22 (11), 2299-2308.e5. doi: 10.1016/j.cgh.2024.04.019

Effects of Thiopurine Withdrawal on Vedolizumab-Treated Patients With Ulcerative Colitis: a Randomized Controlled Trial

2024

Conference Publication

Dose Escalated Ustekinumab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

Barnett, Meghan I., McNamara, Jack, Wilson, William E., Pipicella, Joseph L., Ghaly, Simon, Gearry, Richard, Begun, Jakob, Williams, Astrid-Jane, Lynch, Kate D., Lawrance, Ian C., Schultz, Michael, Walker, Gareth J., Radford-Smith, Graham L., Connor, Susan J. and Andrews, Jane M. (2024). Dose Escalated Ustekinumab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program. Digestive Disease Week (DDW) 2024, Chicago, IL United States, 18-21 May 2024. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(24)03072-5

Dose Escalated Ustekinumab In Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

2024

Journal Article

Systematic review: defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound

Lu, Cathy, Rosentreter, Ryan, Delisle, Maxime, White, Mattie, Parker, Claire E., Premji, Zahra, Wilson, Stephanie R., Baker, Mark E., Bhatnagar, Gauraang, Begun, Jakob, Bruining, David H., Bryant, Robert, Christensen, Britt, Feagan, Brian G., Fletcher, Joel G., Jairath, Vipul, Knudsen, John, Kucharzik, Torsten, Maaser, Christian, Maconi, Giovanni, Novak, Kerri, Rimola, Jordi, Taylor, Stuart A., Wilkens, Rune, Rieder, Florian and The Stenosis Therapy and Anti‐Fibrotic Research (STAR) consortium (2024). Systematic review: defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound. Alimentary Pharmacology and Therapeutics, 59 (8), 928-940. doi: 10.1111/apt.17918

Systematic review: defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound

2024

Journal Article

Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero

Prentice, Ralley, Flanagan, Emma, Wright, Emily K., Gibson, Peter R., Rosella, Sam, Rosella, Ourania, Begun, Jakob, An, Yoon-Kyo, Lawrance, Ian C., Kamm, Michael A., Sparrow, Miles, Goldberg, Rimma, Prideaux, Lani, Vogrin, Sara, Kiburg, Katerina V., Ross, Alyson L., Burns, Megan and Bell, Sally J. (2024). Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero. Clinical Gastroenterology and Hepatology. doi: 10.1016/j.cgh.2024.02.025

Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in-utero

2024

Conference Publication

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

Khoo, E., Amiss, A., Ding, J. N., Bryant, R., Mohsen, W., Connor, S., Leung, R., Croft, A., Lynch, K., Sparrow, M., De Cruz, P., An, Y. K., Holtmann, G. and Begun, J. (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0984

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

2024

Conference Publication

Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib

Gilmore, R., Fernandes, R., Hartley, I., Arzivian, A., Leong, R., Andrew, B., Vasudevan, A., Greeve, T., Moore, G., Kim, S., Lightowler, D., Singh, A., Mahy, G., Mithanthaya, A., Venugpal, K., Han, S., Bryant, R., West, J., Segal, J., Christensen, B., Ding, N. J., An, Y. K. and Begun, J. (2024). Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.1194

Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib

2024

Conference Publication

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

Khoo, E., Amiss, A., Ding, J. N., Bryant, R., Mohsen, W., Connor, S., Leung, R., Croft, A., Lynch, K., Sparrow, M., De Cruz, P., An, Y. K., Holtmann, G. and Begun, J. (2024). Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0984

Tofacitinib demonstrates preliminary efficacy in induction of remission in chronic pouchitis

2024

Conference Publication

Risk of infection after acute severe ulcerative colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study

Kim, S. J., Kim, D. H., Park, S. H., Kim, K. O., Lee, Y. J., Song, E. M., Kim, E. S., Lee, H. S., An, Y. K., Begun, J., Ruddick-Collins, L., Fernandes, R., Liu, J., Cao, Q., Kobayashi, T. and Wei, S. C. (2024). Risk of infection after acute severe ulcerative colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study. 19th Congress of ECCO, Stockholm, Sweden, 21-24 February 2024. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjad212.0892

Risk of infection after acute severe ulcerative colitis in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study

Funding

Current funding

  • 2023 - 2028
    Immunity, Infection and Inflammation Program at MRI-UQ
    Mater Foundation
    Open grant

Past funding

  • 2019
    Improving IBD treatment through harnessing the microbiome and improving outcomes in young adults with IBD
    Ferguson Foundation (Reginald Ferguson)
    Open grant
  • 2018 - 2020
    Mater Health Services IBD Biobank
    Research Donation Generic
    Open grant
  • 2018 - 2022
    The regulatory role of Clec12A in antigen presentation and inflammatory disease (NHMRC Project Grant led by Monash University)
    Monash University
    Open grant
  • 2017
    Identification of novel genetic causes of ulcerative colitis to inform individualised treatment
    Sylvia and Charles Viertel Charitable Foundation
    Open grant
  • 2015 - 2016
    Improving IBD treatment through an understanding of genetics and obstacles to adolescent care
    Ferguson Foundation (Reginald Ferguson)
    Open grant
  • 2014 - 2015
    Towards an oral IL-22 agonist for ulcerative colitis
    Ferring Research Institute
    Open grant

Supervision

Availability

Associate Professor Jakob Begun is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Reducing post-operative Crohn's disease recurrence

    Principal Advisor

    Other advisors: Professor David Clark

  • Doctor Philosophy

    A randomised, open-label, non-inferiority study of upadacitinib compared with oral prednisolone

    Principal Advisor

  • Doctor Philosophy

    Microbial Regulation of Host Inflammatory Pathways in Inflammatory Bowel Disease

    Principal Advisor

    Other advisors: Professor Mark Morrison, Dr Anuj Sehgal

  • Doctor Philosophy

    Study of TOfacitinib for the treatment of chronic Pouchitis

    Principal Advisor

    Other advisors: Professor Gerald Holtmann

  • Doctor Philosophy

    Study of TOfacitinib for the treatment of chronic Pouchitis

    Principal Advisor

    Other advisors: Professor Gerald Holtmann

  • Doctor Philosophy

    Bacteria x Archaea Interactions in Crohn's disease

    Associate Advisor

    Other advisors: Professor Mark Morrison

  • Doctor Philosophy

    Medicinal chemistry of new Nature-inspired treatments for Inflammatory Bowel Disease (IBD)

    Associate Advisor

    Other advisors: Dr Angela Salim, Dr Zeinab Khalil, Professor Rob Capon

  • Doctor Philosophy

    Designer Nanoparticles for Oral and Targeted Delivery of Protein Therapeutics

    Associate Advisor

    Other advisors: Dr Md Moniruzzaman, Associate Professor Amirali Popat

  • Doctor Philosophy

    Designer Nanoparticles for Oral and Targeted Delivery of Protein Therapeutics

    Associate Advisor

    Other advisors: Dr Md Moniruzzaman, Associate Professor Amirali Popat

  • Doctor Philosophy

    Defining the Role of the Mucosa-Associated Microbiota in Digestive Health and Disease Using Novel ex-vivo Combinations of Microbe Culture with Metagenomics

    Associate Advisor

    Other advisors: Professor Mark Morrison

Completed supervision

Media

Enquiries

Contact Associate Professor Jakob Begun directly for media enquiries about:

  • adolescent
  • autophagy
  • Crohn's disease
  • Inflammatory Bowel Disease
  • ulcerative colitis

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au